TCGA-B6-A0WW-01A-11R-A109-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 19
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.430
- OXIDATIVE_PHOSPHORYLATION+0.400
- PROTEIN_SECRETION+0.320
- ANGIOGENESIS+0.310
- UV_RESPONSE_DN+0.250
- PI3K_AKT_MTOR_SIGNALING+0.240
- TGF_BETA_SIGNALING+0.240
- PEROXISOME+0.230
- CHOLESTEROL_HOMEOSTASIS+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.360
- MYC_TARGETS_V2-0.320
- IL6_JAK_STAT3_SIGNALING-0.260
- HEDGEHOG_SIGNALING-0.230
- INFLAMMATORY_RESPONSE-0.220
- TNFA_SIGNALING_VIA_NFKB-0.190
- KRAS_SIGNALING_UP-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.150
- IL2_STAT5_SIGNALING-0.110
- NOTCH_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0B1-01A-12R-A056-07 | — | B | 0.722 |
| 2 | SRR1313114 | — | B | 0.654 |
| 3 | TCGA-BH-A1F8-01A-11R-A13Q-07 | — | B | 0.650 |
| 4 | 713c3ad2-c1d0-45ed-b69e-f6cedd57933a | — | — | 0.642 |
| 5 | TCGA-AR-A24N-01A-11R-A169-07 | — | B | 0.633 |
| 6 | 16dd072b-b664-43e8-8862-c9d9d945f8bc | — | — | 0.624 |
| 7 | b0363d99-5ff4-42cd-849d-79dfad0eaf49 | — | — | 0.621 |
| 8 | SRR23303763 | — | — | 0.619 |
| 9 | MNG554 | — | — | 0.619 |
| 10 | SRR6013598 | — | cohortA4 | 0.606 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |